ସେମିପ୍ଲିମାବ

ସେମିପ୍ଲିମାବ
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	PD-1
Clinical data
Pronunciation	sem' ip li" mab
Trade names	Libtayo
Synonyms	REGN-2810, REGN2810, cemiplimab-rwlc
AHFS/Drugs.com	monograph
MedlinePlus	a618054
data	US DailyMed: Cemiplimab;
Pregnancy; category	AU: D ; US: N (Not classified yet) ; ;
Routes of; administration	Intravenous infusion
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	19 days
Chemical and physical data
Formula	C6380H9808N1688O2000S44
Molar mass	୧,୪୩,୫୬୯.୧0 g·mol−1

ସେମିପ୍ଲିମାବ, ଏକ ବିକ୍ରୟ ନାମ ଲିବଟାୟୋ, ହେଉଛି ସ୍କ୍ୱାମସ ସେଲ ଚର୍ମ କର୍କଟ, ବାସାଲ୍ ସେଲ କର୍କଟ ଏବଂ କେତେକ ଅଣ-ଛୋଟ କୋଷ ଫୁସଫୁସ କର୍କଟ (NSCLC)ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ । ^[୪] ^[୫] ଏହା ଉନ୍ନତ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯାହା ଅସ୍ତ୍ରୋପଚାରଦ୍ୱାରା ଆରୋଗ୍ୟ ହୋଇପାରିବ ନାହିଁ । ^[୪] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଦିଆଯାଏ । ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କମ୍ ଥାଇରଏଡ୍ ସ‌ହିତ କ୍ଳାନ୍ତି ଏବଂ ଓଜନ ବୃଦ୍ଧି; ଅଣନିଶ୍ୱାସ ଏବଂ କାଶ ସହିତ ନିମୋନିଆ; ଚର୍ମ ପ୍ରତିକ୍ରିୟା; ଅଧିକ ଝାଳ, ଉଚ୍ଚ ଥାଇରଏଡ୍ ଓ ଏବଂ ଯକୃତର ପ୍ରଦାହ ହୋଇପାରେ ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଇନଫ୍ୟୁଜନ୍ ପ୍ରତିକ୍ରିୟା ଏବଂ ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା ହୋଇପାରେ । ^[୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ । ^[୫] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ପ୍ରୋଗ୍ରାମ ହୋଇଥିବା ଡେଥ ରିସେପ୍ଟର - ୧ (PD-1) ସହିତ ବାନ୍ଧନ ଯୁକ୍ତ ହୋଇଥାଏ, ଯାହାଟି କୋଷଦ୍ୱାରା କର୍କଟ କୋଷକୁ ମାରିବାକୁ ଦେଇଥାଏ । ^[୪]

୨୦୧୮ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୯ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ସେମିପ୍ଲିମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୪] ଜୁଲାଇ ୨୦୨୦ରେ ଅଷ୍ଟ୍ରେଲିଆରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଏହା ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ଯୁକ୍ତରଜ୍ୟରେ ୩ ସପ୍ତାହ ନିମନ୍ତେ ଏହାର ଖର୍ଚ୍ଚ ୪୬୫୦ ପାଉଣ୍ଡ ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୯,୮୦୦ ଡଲାର ଅଟେ । ^[୮]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ "Libtayo Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 29 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
↑ "AusPAR: Cemiplimab" (PDF). Therapeutic Goods Administration (TGA). 9 November 2020. Archived (PDF) from the original on 7 June 2021. Retrieved 6 June 2021.
↑ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 2021-06-07. Retrieved 2021-06-13.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Libtayo EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 23 June 2020. Retrieved 7 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Libtayo- cemiplimab-rwlc injection". DailyMed. 25 June 2020. Archived from the original on 17 October 2020. Retrieved 16 August 2020.
↑ "FDA approves first treatment for advanced form of the second most common skin cancer". U.S. Food and Drug Administration. 28 September 2018. Archived from the original on 8 August 2020. Retrieved 7 August 2020. This article incorporates text from this source, which is in the public domain.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 912. ISBN 978-0857114105.
↑ "Libtayo Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 January 2021. Retrieved 2 January 2022.

[Au2021-1] ୧.୦ ^୧.୧ "Libtayo Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 29 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.

[2] "AusPAR: Cemiplimab" (PDF). Therapeutic Goods Administration (TGA). 9 November 2020. Archived (PDF) from the original on 7 June 2021. Retrieved 6 June 2021.

[3] "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 2021-06-07. Retrieved 2021-06-13.

[EPAR2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Libtayo EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 23 June 2020. Retrieved 7 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2021-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Libtayo- cemiplimab-rwlc injection". DailyMed. 25 June 2020. Archived from the original on 17 October 2020. Retrieved 16 August 2020.

[FDA_PR-6] "FDA approves first treatment for advanced form of the second most common skin cancer". U.S. Food and Drug Administration. 28 September 2018. Archived from the original on 8 August 2020. Retrieved 7 August 2020. This article incorporates text from this source, which is in the public domain.

[BNF81-7] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 912. ISBN 978-0857114105.

[Price2021USA-8] "Libtayo Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 January 2021. Retrieved 2 January 2022.

[୧]

[୨]

[୩]

[୫]

[୬]

[୪]

[୭]

[୮]